Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy

Summary

Comparison of esophagectomy with Two-field Versus Three-field lymphadenectomy in locally advanced ESCC patients after neoadjuvant therapy

Conditions

• Esophageal Squamous Cell Carcinoma

Interventions

PROCEDURE

Two-Field lymph node dissection

The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with "Two-Field" or "Three-Field" lymph node dissection.

PROCEDURE

Three-Field lymph node dissection

The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with "Two-Field" or "Three-Field" lymph node dissection.

PROCEDURE

Three-Field lymph node dissection

The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and "Three-Field" lymph node dissection will be performed.

Sponsors & Collaborators

• Baoji Central Hospital

  collaborator OTHER

• Sixth Affiliated Hospital, Sun Yat-sen University

  collaborator OTHER

• Suining Central Hospital

  collaborator OTHER

• Jieyang People's Hospital

  collaborator OTHER

• Second Affiliated Hospital of Nantong University

  collaborator OTHER

• Taixing People's Hospital

  collaborator OTHER

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• Suzhou Municipal Hospital

  collaborator OTHER

• Fujian Provincial Hospital

  collaborator OTHER

• Jining First People's Hospital

  collaborator OTHER

• The General Hospital of Western Theater Command

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Shanghai Chest Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-07-01

Primary Completion

2024-06-01

Completion

2027-06-01

Countries

• China

Study Locations